Related Experiment Video
Updated: Aug 16, 2026
Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
p53 expression in Langerhans cell histiocytosis
M Weintraub1, K G Bhatia, R S Chandra
1Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Insights
p53 protein is found in Langerhans cell histiocytosis (LCH) cells but not normal cells. Its presence, without gene mutation, suggests abnormal regulation may drive LCH cell proliferation.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Langerhans cell histiocytosis (LCH) is a rare disorder characterized by abnormal proliferation of Langerhans cells.
- The exact cause of LCH remains unknown, prompting investigation into cellular mechanisms.
- p53 is a critical regulator of cell proliferation and a tumor suppressor protein.
Purpose of the Study:
- To investigate the role of p53 expression in the pathogenesis of Langerhans cell histiocytosis (LCH).
- To determine if p53 gene mutations or abnormal expression contribute to LCH development.
Main Methods:
- Studied LCH lesions from 10 patients using immunohistochemistry for p53 protein detection.
- Assessed p53 gene mutations via single-strand conformation polymorphism (SSCP) analysis.
- Evaluated expression of the p53 binding protein, mdm2.
Main Results:
- p53 protein was detected in all examined LCH biopsy specimens.
- p53 expression was specific to Langerhans cells (LCH cells) and located in the nucleus.
- No p53 gene mutations or abnormal mdm2 expression were found in LCH cells.
Conclusions:
- p53 is present in LCH cells but absent in normal cells, indicating an abnormality.
- The absence of p53 mutations suggests altered p53 regulation (overexpression or post-translational changes) may be involved.
- Dysregulation of p53 in LCH could lead to uncontrolled cell proliferation or programmed cell death induction.
Purpose:
Langerhans cell histiocytosis (LCH) is a disorder of unknown etiology involving the proliferation and accumulation of cells with the phenotype of a bone marrow-derived antigen-presenting cell of the skin, the Langerhans cell. We have studied p53 expression, an element in the control of cell proliferation, to determine whether it plays a role in the pathogenesis of LCH.
Patients And Methods:
LCH lesions from 10 patients with either localized (n = 5) or multisystem disease (n = 5) were studied. p53 protein expression was assessed by immunohistochemistry, and p53 gene mutation by the single strand conformation polymorphism (SSCP) technique.
Results:
p53 protein expression was detected in all 10 LCH biopsy specimens examined. It was restricted to Langerhans cells (LCH cells), absent from adjacent cells, and localized to the cell nuclei. No mutations of the p53 gene were detected, nor was there abnormal expression of the p53 binding protein, mdm2.
Conclusions:
p53 is readily detectable in LCH cells but not in normal cells. This is either caused by an unusual mechanism (given the absence of mutations in the p53 gene and of mdm2 expression in LCH cells) or by overexpression or posttranslational changes of normal p53 in response to an as yet unidentified cellular stress. Stabilization and inactivation of p53 could lead to the uncontrolled proliferation of LCH cells, or the abnormality could lead to the induction of programmed cell death.
